{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:11:17Z","timestamp":1783905077995,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,12]]},"DOI":"10.7759\/cureus.112517","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:39:22Z","timestamp":1783903162000},"source":"Crossref","is-referenced-by-count":0,"title":["Transient Neonatal Myasthenia Gravis in a Newborn Infant Presenting to an Emergency Department"],"prefix":"10.7759","author":[{"given":"Marice","family":"Salib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy Y","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"30","author":"Vincent A","year":"2001","unstructured":"Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001, 30:2122-8. 10.1016\/S0140-6736(00)05186-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga AR","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022, 21:176-88. 10.1016\/S1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214139","article-title":"Obstetric and neonatal outcomes in patients with maternal myasthenia gravis: a nationwide cohort study","volume":"105","author":"Lindroos JL","year":"2025","unstructured":"Lindroos JL, Bj\u00f8rk MH, Cohen JM, Danielsson KC, Hikmat O, Hoff JM, Gilhus NE. Obstetric and neonatal outcomes in patients with maternal myasthenia gravis: a nationwide cohort study. Neurology. 2025, 105:e214139. 10.1212\/WNL.0000000000214139","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041136","article-title":"Transient neonatal myasthenia gravis as a common complication of a rare disease: a systematic review","volume":"13","author":"Lindroos JL","year":"2024","unstructured":"Lindroos JL, Bj\u00f8rk MH, Gilhus NE. Transient neonatal myasthenia gravis as a common complication of a rare disease: a systematic review. J Clin Med. 2024, 13:1136. 10.3390\/jcm13041136","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-021-00970-6","article-title":"Transient neonatal myasthenia gravis: refining risk estimate for infants born to women with myasthenia gravis","volume":"41","author":"Kochhar PK","year":"2021","unstructured":"Kochhar PK, Schumacher RE, Sarkar S. Transient neonatal myasthenia gravis: refining risk estimate for infants born to women with myasthenia gravis. J Perinatol. 2021, 41:2279-83. 10.1038\/s41372-021-00970-6","journal-title":"J Perinatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli MN","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8:475-90. 10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group","volume":"85","author":"Norwood F","year":"2014","unstructured":"Norwood F, Dhanjal M, Hill M, et al.. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry. 2014, 85:538-43. 10.1136\/jnnp-2013-305572","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13788","article-title":"Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence","volume":"25","author":"Gilhus NE","year":"2018","unstructured":"Gilhus NE, Hong Y. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol. 2018, 25:1402-9. 10.1111\/ene.13788","journal-title":"Eur J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2178302","article-title":"Treatment considerations in myasthenia gravis for the pregnant patient","volume":"23","author":"Gilhus NE","year":"2023","unstructured":"Gilhus NE. Treatment considerations in myasthenia gravis for the pregnant patient. Expert Rev Neurother. 2023, 23:169-77. 10.1080\/14737175.2023.2178302","journal-title":"Expert Rev Neurother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.10.037","article-title":"Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy","volume":"383","author":"Gamez J","year":"2017","unstructured":"Gamez J, Salvado M, Casellas M, Manrique S, Castillo F. Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy. J Neurol Sci. 2017, 383:118-22. 10.1016\/j.jns.2017.10.037","journal-title":"J Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad153","article-title":"The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD)","volume":"146","author":"Allen NM","year":"2023","unstructured":"Allen NM, O'Rahelly M, Eymard B, et al.. The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD). Brain. 2023, 146:4233-46. 10.1093\/brain\/awad153","journal-title":"Brain"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/497167-transient-neonatal-myasthenia-gravis-in-a-newborn-infant-presenting-to-an-emergency-department","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:39:23Z","timestamp":1783903163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/497167-transient-neonatal-myasthenia-gravis-in-a-newborn-infant-presenting-to-an-emergency-department"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.112517","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}